Urocortin-2 suppression of p38-MAPK signaling as an additional mechanism for ischemic cardioprotection

[1]  Chun-Fa Huang,et al.  Chloroacetic acid induced neuronal cells death through oxidative stress-mediated p38-MAPK activation pathway regulated mitochondria-dependent apoptotic signals. , 2013, Toxicology.

[2]  A. Berger,et al.  Sensitization of melanoma cells for TRAIL-induced apoptosis by BMS-345541 correlates with altered phosphorylation and activation of Bax , 2013, Cell Death and Disease.

[3]  M. Marber,et al.  New therapeutic targets in cardiology: p38 alpha mitogen-activated protein kinase for ischemic heart disease. , 2012, Circulation.

[4]  Xiuli Yi,et al.  Baicalein protects human melanocytes from H₂O₂-induced apoptosis via inhibiting mitochondria-dependent caspase activation and the p38 MAPK pathway. , 2012, Free radical biology & medicine.

[5]  G. Ghatnekar,et al.  2‐Methoxyestradiol induced bax phosphorylation and apoptosis in human retinoblastoma cells via p38 MAPK activation , 2012, Molecular carcinogenesis.

[6]  C. Kirkpatrick,et al.  Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep , 2012, British journal of pharmacology.

[7]  E. Marcotte,et al.  Insights into the regulation of protein abundance from proteomic and transcriptomic analyses , 2012, Nature Reviews Genetics.

[8]  L. Blatter,et al.  Measuring mitochondrial function in intact cardiac myocytes. , 2012, Journal of molecular and cellular cardiology.

[9]  P. Grammas,et al.  p38 MAPK: a mediator of hypoxia-induced cerebrovascular inflammation. , 2012, Journal of Alzheimer's disease : JAD.

[10]  T. Force,et al.  A novel cardioprotective p38-MAPK/mTOR pathway. , 2011, Experimental cell research.

[11]  Hyung-Hwan Kim,et al.  The functions of mTOR in ischemic diseases. , 2011, BMB reports.

[12]  Y. Oh,et al.  Translocation and oligomerization of Bax is regulated independently by activation of p38 MAPK and caspase-2 during MN9D dopaminergic neurodegeneration , 2011, Apoptosis.

[13]  Juejin Wang,et al.  Corticotropin-releasing factor family and its receptors: pro-inflammatory or anti-inflammatory targets in the periphery? , 2011, Inflammation Research.

[14]  A. Strasser,et al.  The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy , 2011, Cell Death and Differentiation.

[15]  G. Faggian,et al.  Activation of Src protein tyrosine kinase plays an essential role in urocortin-mediated cardioprotection , 2010, Molecular and Cellular Endocrinology.

[16]  K. Peterson,et al.  Acute effects of urocortin 2 on cardiac function and propensity for arrhythmias in an animal model of hypertension‐induced left ventricular hypertrophy and heart failure , 2010, European journal of heart failure.

[17]  M. Hubank,et al.  New targets of urocortin-mediated cardioprotection , 2010, Journal of molecular endocrinology.

[18]  P. Peeters,et al.  Corticotropin releasing factor-induced ERK phosphorylation in AtT20 cells occurs via a cAMP-dependent mechanism requiring EPAC2 , 2010, Neuropharmacology.

[19]  Derek W. Yecies,et al.  MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterparts , 2009, The Journal of cell biology.

[20]  Juejin Wang,et al.  Urocortin induced expression of COX‐2 and ICAM‐1 via corticotrophin‐releasing factor type 2 receptor in rat aortic endothelial cells , 2009, British journal of pharmacology.

[21]  T. Kourelis,et al.  Urocortin induces interleukin-6 release from rat cardiomyocytes through p38 MAP kinase, ERK and NF-kappaB activation. , 2009, Journal of molecular endocrinology.

[22]  A. Letai,et al.  Control of mitochondrial apoptosis by the Bcl-2 family , 2009, Journal of Cell Science.

[23]  R. Meller.  The Role of the Ubiquitin Proteasome System in Ischemia and Ischemic Tolerance , 2009, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[24]  S. Lloyd,et al.  Low carbohydrate diet decreases myocardial insulin signaling and increases susceptibility to myocardial ischemia. , 2008, Life sciences.

[25]  V. Borutaite.  AMPK, MAPK and Bax in the heart: some questions answered. , 2008, The Biochemical journal.

[26]  A. Richards,et al.  Urocortin 2 combined with angiotensin-converting enzyme inhibition in experimental heart failure. , 2008, Clinical science.

[27]  R. Knight,et al.  Urocortin prevents mitochondrial permeability transition in response to reperfusion injury indirectly by reducing oxidative stress. , 2007, American journal of physiology. Heart and circulatory physiology.

[28]  E. Zorrilla,et al.  Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: Ancient CRF paralogs , 2007, Frontiers in Neuroendocrinology.

[29]  S. Lloyd,et al.  A Comparison between Ranolazine and CVT-4325, a Novel Inhibitor of Fatty Acid Oxidation, on Cardiac Metabolism and Left Ventricular Function in Rat Isolated Perfused Heart during Ischemia and Reperfusion , 2007, Journal of Pharmacology and Experimental Therapeutics.

[30]  C. Tsatsanis,et al.  Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti‐inflammatory effect during the early phase of inflammation suppressing LPS‐induced TNF‐α release from macrophages via induction of COX‐2 and PGE2 , 2007, Journal of cellular physiology.

[31]  W. Holman,et al.  Sodium-hydrogen exchange inhibition and beta-blockade additively decrease infarct size. , 2007, The Annals of thoracic surgery.

[32]  Azad Bonni,et al.  p38 MAP Kinase Mediates Apoptosis through Phosphorylation of BimEL at Ser-65* , 2006, Journal of Biological Chemistry.

[33]  S. Korsmeyer,et al.  Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[34]  D. Latchman,et al.  Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. , 2004, Endocrinology.

[35]  A. Stephanou,et al.  Protective effects of the urocortin homologues stresscopin (SCP) and stresscopin-related peptide (SRP) against hypoxia/reoxygenation injury in rat neonatal cardiomyocytes. , 2003, Journal of molecular and cellular cardiology.

[36]  D. Latchman,et al.  Urocortin protects the heart from reperfusion injury via upregulation of p42/p44 MAPK signaling pathway. , 2002, American journal of physiology. Heart and circulatory physiology.

[37]  H. Randeva,et al.  Urocortin, but not corticotropin-releasing hormone (CRH), activates the mitogen-activated protein kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1alpha and R2beta CRH receptor subtypes and stimulation of Gq-proteins. , 2000, Molecular endocrinology.

[38]  J. Martinou,et al.  Mitochondria as the central control point of apoptosis. , 2000, Trends in cell biology.

[39]  T. Yue,et al.  Inhibition of p38 mitogen-activated protein kinase decreases cardiomyocyte apoptosis and improves cardiac function after myocardial ischemia and reperfusion. , 1999, Circulation.

[40]  T. Chittenden,et al.  Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Y. Hsu,et al.  Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.